Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1HER2-positive Gastric Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 14sintilimab 10S 1 (combination) 9Drug Therapy 7Capecitabine 5tislelizumab 4Surgical Procedures, Operative 4Paclitaxel 4HMPL-013 4apatinib 3Tegafur 3Immune Checkpoint Inhibitors 3Cisplatin 3Bevacizumab 3surufatinib 2potassium oxonate 2lenvatinib 2irinotecan sucrosofate 2gimeracil 2Observation 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorouracil 2Exercise 2Endoscopic Mucosal Resection 2Doxorubicin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zolbetuximab 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Stomach Neoplasms × disitamab vedotin × Clear all
NCT06385873 2024-05-13

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
32 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡